Allergic Rhinitis Prevention — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for allergic rhinitis prevention. 60 active patents protecting 3 drugs from 3+ originators. First major cliff: 2027. Daily refresh.

3
Approved drugs
60
Active US patents
64/100
Avg vulnerability
$5.6B
Annual revenue covered

Originators in Allergic Rhinitis Prevention

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca K.K. 37 patents Merck & Co. 22 patents Padagis Us 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating allergic rhinitis prevention. Each bar = one year. Y-axis scaled to peak year (16 patents).

7
26
2
27
2
28
3
29
8
30
7
31
1
32
16
34
4
36
3
38
3
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Pulmicort Respules
BUDESONIDE
 AstraZeneca K.K. 37 68 $2.8B 2026-11-09
Elocon
MOMETASONE FUROATE
 Merck & Co. 22 44 — 2026-11-29
Verdeso
DESONIDE
 Padagis Us 1 80 $2.8B 2027-08-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8497258 Pulmicort Respules method of use 93 2026-11-09
9119863 Pulmicort Respules method of use 93 2026-11-09
8975243 Pulmicort Respules method of use 93 2026-11-09
11357859 Pulmicort Respules method of use 88 2028-11-12
8491932 Pulmicort Respules method of use 83 2029-05-07
8324192 Pulmicort Respules method of use 81 2029-08-03
8460641 Verdeso method of use 80 2027-08-13
9415009 Pulmicort Respules method of use 76 2030-05-28
10716753 Pulmicort Respules method of use 76 2030-05-28
11564934 Pulmicort Respules method of use 75 2039-01-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303635 Elocon composition of matter 0 2039-04-08
10406332 Elocon formulation 25 2034-03-13
8763222 Elocon formulation 31 2032-02-08
11679210 Elocon formulation 33 2038-09-03
10561672 Elocon formulation 33 2034-09-04
9937189 Elocon formulation 33 2034-09-04
10376526 Elocon formulation 33 2034-09-04
9370483 Elocon formulation 33 2034-09-04
10232152 Elocon method of use 45 2034-11-24
10660858 Pulmicort Respules formulation 48 2031-09-07

Related